Updated time: 2021-11-18 11:25:22
28A-1060418
TW I672504、US 11142795 B2
C-type lectin 18 (CLEC18) is a novel secretory C-type lectin. In our previously CLEC18 was expressed in human hepatocytes, kidney, pancreas and genitourinary system. Hepatitis B virus (HBV) infection is a global problem. HBV infects liver and leads to cirrhosis and hepatocellular carcinoma (HCC). Evaluation of HBV infectious status is important for disease management in chronic hepatitis B (CHB) patients. Currently, no single serum marker can reflect the disease status, including fibrosis stage in CHB patients, and treatment outcome. Our human CLEC18 antibody (Clone 3A9E6, 3F10F8) is well for detection of CLEC18 in human tissues. CLEC18 is a potential biomarker for viral hepatitis, liver fibrosis, HCC and prognostic of HBV infection.
There was a Commercial CLEC18 ELISA kit(CUSABIO, code:CSB-EL005521HU), however it cannot detect CLEC18 recombinant protein and had lower detection level of human plasma CLEC18 compared to our human CLEC18 antibody (Clone 3A9E6, 3F10F8).
1. CLEC18 as a biomarker for predict HbeAg loss and seroconversion in interferon treated CHB patients.
2. CLEC18 as a biomarker for inflammation, liver fibrosis and cirrhosis in viral or autoimmune hepatitis and steatosis patients.
3. CLEC18 as a biomarker for disease progression and treatment prognostic factor in CHC infected patients.
4. CLEC18 as a biomarker for disease progression and treatment prognostic factor in renal failure patients.
5. CLEC18 as a biomarker for disease progression and treatment prognostic factor in autoimmune disease.
Shie-Liang Hsieh, Ya-Lang Huang, Tsung-Yu Tsai
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Plasma CLEC18 as the biomarker for liver cirrhosis